Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis

Masashi Bando, Hiroyoshi Yamauchi, Takashi Ogura, Hiroyuki Taniguchi, Kentaro Watanabe, Arata Azuma, Sakae Homma, Yukihiko Sugiyama, K. Chida, N. Keicho, Y. Nakanishi, N. Inase, M. Nishimura, Y. Inoue, H. Mukae, A. Yokoyama, Y. Taguchi, H. Takizawa, M. Mishima, Y. NishiokaY. Ishii, M. Munakata, N. Kohno, Hiroshima K. Kishi

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was-30±224 (SD) mL in the first year of treatment,-158±258 mL in the second year, and-201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalInternal Medicine
Volume55
Issue number5
DOIs
Publication statusPublished - Mar 1 2016

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this